GOVERNMENT OF INDIA
MINISTRY OF AYURVEDA, YOGA & NATUROPATHY,
UNANI, SIDDHA AND HOMOEOPATHY
(AYUSH)

LOK SABHA
UNSTARRED QUESTION NO.2063
TO BE ANSWERED ON 12TH February, 2021

AYUSH DRUG FOR BREAST CANCER

2063. SHRI ADALA PRABHAKARA REDDY:
SHRI LAVU SRI KRISHNA DEVARAYALU:
SHRIMATI CHINTA ANURADHA:
DR. BEESETTI VENKATA SATYAVATHI:
SHRI MAGUNTA SREENIVASULU REDDY:
SHRI CHANDRA SEKHAR BELLANA:

Will the Minister of AYURVEDA, YOGA AND NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY (AYUSH) be pleased to state:

(a) whether the Central Council for Research in Ayurvedic Sciences (CCRAS) in collaboration with AIIMS, New Delhi has conducted a clinical research study for evaluating Quality of Life with a coded Ayurvedic formulation namely ‘AYUSH QOL-2C’ in patients of local non-metastatic Breast Cancer treated with Adjuvant Chemotherapy/Radiotherapy and correlating it with Molecular Marker;

(b) if so, the details thereof;

(c) whether the Government has granted approval for manufacturing this drug; and

(d) if so, the details thereof and if not, the reasons therefor?

ANSWER

THE MINISTER OF STATE (IC) OF THE MINISTRY OF YOUTH AFFAIRS AND SPORTS AND ADDITIONAL CHARGE OF MINISTER OF STATE (IC) OF THE MINISTRY OF AYURVEDA, YOGA & NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY
(SHRI KIREN RIJIJU)

(a): Yes.

(b): The Central Council for Research in Ayurvedic Sciences (CCRAS), which is an autonomous body under the aegis of Ministry of AYUSH, in collaboration with AIIMS, New Delhi, has conducted a prospective double blind randomized placebo controlled clinical trial entitled “A Pilot Study Evaluating Quality of Life with AYUSH QOL - 2C in Patients of Local Non-Metastatic Breast Cancer Treated with Adjuvant Chemotherapy/Radiotherapy and Correlating it with Molecular Marker” The study revealed a trend towards better local control and survival in the “AYUSH QOL 2 C” Group and the drug was safe and well tolerated.
(c) & (d): The Ayurvedic formulation “Ayush QOL 2 C” has been developed by the Council and the patent has been filed. The grant of patent is awaited. The efforts are being made by the Council for technology transfer through National Research Development Corporation (NRDC) as per commercialization policy of CCRAS.